Sequoia Financial Advisors LLC Sells 2,037 Shares of Stryker Corporation $SYK

Sequoia Financial Advisors LLC lessened its stake in Stryker Corporation (NYSE:SYK) by 14.0% in the 2nd quarter, Holdings Channel reports. The institutional investor owned 12,466 shares of the medical technology company’s stock after selling 2,037 shares during the quarter. Sequoia Financial Advisors LLC’s holdings in Stryker were worth $3,925,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Sankala Group LLC bought a new stake in Stryker in the 4th quarter valued at $26,000. Godfrey Financial Associates Inc. bought a new position in Stryker during the 4th quarter worth about $26,000. United Financial Planning Group LLC bought a new position in Stryker during the 3rd quarter worth about $27,000. Atlas Capital Advisors Inc. acquired a new stake in shares of Stryker in the 4th quarter valued at about $27,000. Finally, Gables Capital Management Inc. bought a new stake in shares of Stryker in the second quarter valued at about $25,000. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Stryker Stock Performance

SYK opened at $275.28 on Friday. The business’s 50-day simple moving average is $324.62 and its 200 day simple moving average is $326.48. Stryker Corporation has a 52-week low of $267.00 and a 52-week high of $392.55. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16. The firm has a market capitalization of $105.59 billion, a PE ratio of 28.53, a PEG ratio of 1.73 and a beta of 0.76.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, beating analysts’ consensus estimates of $3.49 by $0.20. The firm had revenue of $6.59 billion during the quarter, compared to the consensus estimate of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The business’s revenue was up 9.4% compared to the same quarter last year. During the same period last year, the company earned $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, sell-side analysts expect that Stryker Corporation will post 15.02 earnings per share for the current fiscal year.

Stryker Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 1.3%. The ex-dividend date of this dividend is Wednesday, September 30th. Stryker’s dividend payout ratio is 36.48%.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the company. Royal Bank Of Canada reduced their price objective on Stryker from $435.00 to $420.00 and set an “outperform” rating for the company in a research report on Friday, July 31st. UBS Group assumed coverage on Stryker in a research note on Tuesday, July 28th. They issued a “buy” rating and a $400.00 target price on the stock. Wall Street Zen raised Stryker from a “hold” rating to a “buy” rating in a research report on Saturday, August 8th. BMO Capital Markets reiterated an “outperform” rating and issued a $317.00 price objective on shares of Stryker in a report on Wednesday. Finally, Citizens Jmp cut their price objective on shares of Stryker from $440.00 to $400.00 and set a “market outperform” rating on the stock in a research report on Monday, August 3rd. Eighteen equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to MarketBeat.com, Stryker has a consensus rating of “Moderate Buy” and an average price target of $380.40.

Insiders Place Their Bets

In other Stryker news, Director Ronda Stryker sold 50,000 shares of the stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $340.10, for a total value of $17,005,000.00. Following the completion of the sale, the director owned 2,251,375 shares in the company, valued at $765,692,637.50. This trade represents a 2.17% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Debra King sold 826 shares of Stryker stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total transaction of $277,783.80. Following the completion of the transaction, the insider directly owned 6,210 shares of the company’s stock, valued at approximately $2,088,423. This trade represents a 11.74% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 351,267 shares of company stock valued at $118,197,701. 4.60% of the stock is currently owned by corporate insiders.

Stryker Profile

Stryker Corporation is a global medical technology company headquartered in Portage, Michigan. The company develops and manufactures products used by hospitals, physicians and other healthcare providers across a range of medical specialties.

Stryker’s principal businesses include orthopaedics, medical and surgical equipment, and neurovascular products. Its offerings include joint replacement and trauma implants, spinal devices, surgical instruments, operating-room equipment, endoscopy systems, surgical navigation technologies, emergency-care products and devices used to treat neurovascular conditions such as stroke.

Founded in 1941 by Dr.